• NU6300 Targets GSDMD Cys191 to Block Pyroptosis

  2026-09-18

  Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that reacts with cysteine-191, blocking both GSDMD cleavage and the palmitoylation required for membrane pore formation. The study combines biochemical, cellular, and in vivo inflammation models to show that NU6300 suppresses pyroptosis and improves outcomes in experimental colitis and sepsis.

• CD40–STING–TRAF2 Signaling in ESCC TLS

  2026-09-18

  This study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and links them to activated, IRF4-positive B cells. Its mechanistic contribution is the discovery that CD40 and STING compete for TRAF2, coupling receptor signaling, STING ubiquitination and phosphorylation, and non-canonical NF-κB-dependent B-cell activation.

• H 89 2HCl: PKA Inhibition and cAMP Signaling

  2026-09-17

  H 89 2HCl is a biochemical tool for cAMP-dependent protein kinase inhibition and cellular studies of protein phosphorylation modulation. The compound inhibits PKA with a reported Ki of 48 nM, but its broader kinase activity requires concentration-aware controls and orthogonal validation.

• MLN2238: Mapping Proteasome Stress Responses

  2026-09-17

  MLN2238 is a selective proteasome β5 subunit inhibitor that can be used not only to study proteasome blockade, but also to map adaptive stress signaling. This article translates CRTC-CREB research into a decision framework for oncology, proteostasis, and resistance-focused assays.

• Cy5-UTP for Mechanistic RNA Imaging

  2026-09-16

  Cy5-UTP enables direct fluorescent RNA labeling for FISH, expression analysis, and RNA probe synthesis. This article explains how to use Cyanine 5-uridine triphosphate as an analytical tool for separating RNA production, probe performance, and nanoparticle-mediated delivery effects.

• Rapakinin Signaling in Hypertensive Rat Arteries

  2026-09-16

  The reference study identified rapakinin, an Arg-Ile-Tyr peptide from rapeseed protein, as an endothelium-dependent vasorelaxant in mesenteric arteries from spontaneously hypertensive rats. Pharmacological experiments placed prostaglandin I2 signaling through the IP receptor upstream of CCK1-receptor-dependent relaxation, distinguishing this pathway from the nitric oxide and bradykinin mechanisms commonly associated with ACE-related vasodilation.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-09-15

  Build a dual-readout workflow that separates mRNA uptake from productive protein expression using Cy5 fluorescence and Firefly Luciferase bioluminescence. This guide covers carrier optimization, assay controls, intracellular tracking, and troubleshooting for reproducible mRNA delivery studies.

• CCG-1423: Mechanism of a RhoA Inhibitor

  2026-09-15

  CCG-1423 is a RhoA inhibitor that blocks the MRTF-A/importin α/β1 nuclear-import interaction without disrupting MRTF-A binding to monomeric G-actin. Its documented research uses include cancer research, proliferation and invasion studies, and apoptosis assay design, while a separate 2025 study establishes RhoA/ROCK1/MLC2 signaling as a mechanism of tight-junction disruption during MVC infection.

• PYR-41 for E1 Inhibition in Cell Assays

  2026-09-14

  A scenario-based guide to using PYR-41, inhibitor of Ubiquitin-Activating Enzyme (E1), in cell viability, proliferation, cytotoxicity, and inflammatory signaling workflows. It explains how SKU B1492 can improve experimental interpretability through controlled solvent handling, evidence-linked concentration selection, and appropriate mechanistic controls.

• Urolithin A: Metabolic Assay Design Beyond Mitophagy

  2026-09-14

  Urolithin A research can move beyond simple mitophagy readouts by connecting mitochondrial quality control with cellular carbon metabolism. This article translates hepatic stellate cell findings on SIRT4 and glutamine metabolism into a rigorous, hypothesis-aware assay strategy.

• Fingolimod (FTY720) as a Trafficking Control

  2026-09-13

  Fingolimod (FTY720) is best understood in advanced immunology assays as a compartment- and trafficking-level perturbation, not merely an MS drug. This article connects S1P biology with magnetic CAR-T-mimicking cell research and provides evidence-bounded assay design, controls, and handling guidance.

• DAPI (hydrochloride) Workflow Guide

  2026-09-12

  DAPI (hydrochloride) converts nuclear DNA into a practical readout for cell counting, chromosome staining, histochemistry, and flow-based cell cycle analysis. This guide connects optimized staining conditions with assay design for immuno-oncology studies, including workflows inspired by a recent glabridin–gold(I) investigation.

• WAY-100635: A 5-HT1A Antagonist Research Guide

  2026-09-11

  WAY-100635 is a selective 5-HT1A receptor antagonist for separating serotonergic receptor effects from endocannabinoid, sensory, and affective pain mechanisms. This guide translates recent multidimensional pain findings into practical binding, functional, behavioral, and imaging assay decisions.

• Thapsigargin for SERCA and ER Stress Workflows

  2026-09-11

  Thapsigargin enables fast, controllable disruption of ER calcium handling for calcium imaging, endoplasmic reticulum stress research, and apoptosis assays. This practical guide connects acute signaling measurements with mechanistic validation, including the ER stress–NLRP3 framework reported in cough variant asthma research.

• Dabigatran: From Thrombin Mechanism to Translation

  2026-09-10

  Dabigatran is more than a direct thrombin inhibitor: it is a translational tool for connecting molecular coagulation biology with clinically relevant assay design. This article examines how reversible inhibition of free and fibrin-bound thrombin can guide experimental strategy, how to build robust thrombin inhibition assays and coagulation function tests, and where clinical realities such as renal impairment, bleeding risk, metabolite activity, and formulation constrain interpretation. It also explains how the APExBIO research offering can support reproducible anticoagulation studies beyond the scope of a conventional product page.

8449 records 1/564 page Next 12345 下5页 Last page